Pulse Biosciences will showcase late‑breaking 6‑ and 12‑month follow‑up data from its first‑in‑human feasibility study of the nPulse Cardiac Catheter Ablation System at the 31st Annual AF Symposium, scheduled for February 5‑7, 2026. The presentation will detail safety and efficacy outcomes from a European cohort of 150 patients treated with the company’s nanosecond pulsed‑field ablation (nsPFA) technology, a first‑in‑class approach that delivers non‑thermal, high‑frequency electrical pulses to ablate atrial tissue while sparing surrounding structures.
Continue reading for full analysis...
Pulse Biosciences announced that the U.S. Food and Drug Administration granted an Investigational Device Exemption for its nPulse Cardiac Catheter Ablation System, enabling the company to launch the NANOPULSE‑AF study targeting paroxysmal atrial fibrillation. The single‑arm, multicenter trial will enroll up to 145 patients at 30 sites, including three international locations, and will evaluate the safety and effectiveness of the company’s nanosecond pulsed‑field ablation (nsPFA) technology for durable pulmonary vein isolation.
Continue reading for full analysis...